Table 2 Effect on prophylactic chemo-immunotherapy on tumorigenesis and tumor spectrum in MLH1−/− mice
From: Chemo-immunotherapy improves long-term survival in a preclinical model of MMR-D-related cancer
Intervention | mean age of onset [weeks ± SD] | tumor type [%] | mice [%] | |||
|---|---|---|---|---|---|---|
Lymphoma | GIT | Lymphoma | GIT | other | tumor free | |
controla | 25.3 ± 11.7 | 35.5 ± 9.3 | 62.1 | 34.7 | 3.2 | 0.0 |
lysate | 30.2 ± 10.0 | 47.4 ± 8.5 | 51.7 | 33.3 | 0.0 | 15.0 |
GEM + vaccine | 23.5 ± 13.4 | 53.4 ± 14.1 | 22.2 | 44.4 | 0.0 | 33.3 |
CPX + vaccine | 34.3 ± 6.9 | 47.7 ± 5.9 | 55.5 | 33.3 | 0.0 | 11.1 |